Contagion Editorial Team

Vedanta Biosciences offered further insights on its completed phase 2 trial for its novel therapeutic, VE303.

The ongoing outbreak in the Democratic Republic of Congo is affecting mostly very young children, and has investigators searching for answers.

Here is a recap of the latest happenings during C diff awareness month.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

The clinical stage company, Recursion, dosed its first participant using a novel therapy that is not an antimicrobial.

Experts highlighted research showing that even mild COVID can result in cognitive impairment including brain fog and IQ decline, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59, E coli outbreak linked to McDonald's Quarter Pounders, and more.

This new indication for the bivalent respiratory syncytial virus prefusion F vaccine (Abrysvo) makes it the broadest currently available.

The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

This week, recent investigations link contaminated ice machines to Burkholderia multivorans infections, the hepatitis treatment market is projected to grow to USD 30.2 billion by 2032, 2020 guidelines recommend targeting specific AUC levels for optimizing vancomycin therapy, and more

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.

The pharmaceutical company said there were no safety issues associated with the decision.

Enanta Pharmaceuticals says its investigational therapy, EDP-323, was found to be safe and efficacious against the respiratory virus.

Get caught up with the latest study information, feedback from people in the field, and news on the latest investigational therapies.

This week, a push for better care standards for C difficile, a survey shows low vaccination rates for respiratory viruses among Americans, Georgia achieves a reduction in chronic hepatitis C infections through collaborative efforts, and more.

The federal agency gave the nod to FluMist nasal spray to allows individuals to administer the vaccine themselves and as a caregivers to others.

This week, World AMR Congress interviews, Long COVID’s toll on the brain, e coli outbreak linked to lettuce, and more.

The platform, PfizerForAll, looks to enable telemedicine for certain health conditions and information about vaccination access.

A study on vancomycin treatment, new data on the investigational Pfizer C diff vaccine, how individual antibiotics are ranked by risk for C difficile infection, and more.

We have complied some of our news stories and interviews from the last week to offer information on the differences between clade I and clade 2 mpox, why WHO declaring the global emergency is significant, looking at mpox in the United States, and more.

The Africa CDC's declaration of the mpox outbreak as a Public Health Emergency of Continental Security, GIGA-2339's upcoming phase 1 trials for HBV, ActivePure Medical's air decontamination system's success in reducing MRSA and HAIs, and more this week from Contagion.

The companies’ study met 1 of their 2 primary immunogenicity objectives.

This is the very first such declaration by the Africa CDC since its inception in 2017.

Enhanced diagnostic and surveillance measures for hypervirulent pathogens, new CDC safety data on RSV vaccines showing rare risks, updated IDSA guidance for managing antimicrobial-resistant infections, and more this week from Contagion.

Recent analysis suggests that stricter COVID-19 measures could have saved thousands, Danjuma Adda calls for more funding and awareness to tackle viral hepatitis, our second episode of From Pathogen to Infectious Disease podcast, and more this week.

Here is a review of the most up-to-date information around the infection.

Merck’s antibody, clesrovimab (MK-1654), is designed to protect infants against medically attended lower respiratory infections (MALRI) caused by RSV.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

A clinical stage company, NanoViricides, is moving forward with their investigational drug, NV-387, into phase 2 clinical trials to examine treatment for RSV, influenza, COVID-19.

A Florida hospital takes a novel approach for the healthcare-associated infection and reduced inappropriate testing by setting up guidelines.